Document:

evok-ex1026_373.htm

Exhibit 10.26

SECOND AMENDMENT TO LEASE

This Second Amendment to Lease (this "Amendment") is made, for reference purposes only, December 6, 2019, by and between SB CORPORATE CENTRE Ill-IV, LLC, a Delaware limited liability company ("Landlord"), and EVOKE PHARMA, INC., a Delaware corporation ("Tenant"), with reference to the following facts:

RECITALS

	
 
	
A.
	
Landlord and Tenant are parties to that certain Office Lease Agreement dated as of December 19, 2016, as amended by that certain First Amendment to Lease dated as of September 27, 2018 (collectively, as amended, the "Lease") for that certain premises located at 420 Stevens Avenue, Suite 370, Solana Beach, California 92075, consisting of approximately 3,031 Rentable Square Feet of commercial office space (the "Premises").
	
 

	
 
	
B.
	
The parties desire to amend the Lease as set forth in this Amendment.

	
 
	
C.
	
All capitalized terms used in this Amendment, unless specifically defined herein, shall have the same meaning as the capitalized terms used in the Lease.
	
 

NOW, THEREFORE, for valuable consideration, the receipt and adequacy of which are expressly acknowledged, Landlord and Tenant agree as follows:

AGREEMENT

1.Extension Term. The term of the Lease for the Premises is set to expire on December 31, 2019. By virtue of this Amendment, Landlord and Tenant hereby agree that the term of the Lease for the Premises shall be extended to and including December 31, 2020 (the "Expiration Date"), subject to the terms and conditions contained herein and the Lease. For the purposes of this Amendment, the period of time between and including January 1, 2020 (the "Extended Term Effective Date") and the Expiration Date shall be referred to herein as, the "Extension Term". Furthermore, any and all previously granted and unexercised options to extend the term of the Lease shall be null and void and of no further force or effect.

2.Rent. Tenant shall pay Basic Monthly Rent to Landlord for the Premises in advance on or before the first day of every calendar month, without any set-off or deduction, pursuant to the current rate as set forth in the Lease. However, as of the Extended Term Effective Date, Tenant's Basic Monthly Rent for the Premises shall be as follows during the Extension Term:

Basic Monthly Rent

Lease PeriodApproximate Rate perActual Total per Month

RSF per Month

1/1/2020-12/31/2020$4.01$12,154.31

3.Tenant Certification. By execution of this Amendment, Tenant hereby certifies that as of the date hereof, neither Tenant nor Landlord is in default of the performance of its obligations pursuant to the Lease, and Tenant has no claim, defense, or offset with respect to the Lease.

4.Real Estate Brokers. Tenant represents and warrants to Landlord that it has not authorized or employed, or acted by implication to authorize or employ, with any real estate broker or sales person to act for it in connection with this Amendment or dealt with any real estate broker or sales person in connection with this Amendment other than RE:Align, Inc. Tenant also agrees to indemnify, defend and hold harmless Landlord from and against any and all claims by any real estate broker or salesman whom the Tenant authorized or employed, or acted by implication to authorize or employ, to act for Tenant in connection with this Amendment, or with any broker or sales person with whom Tenant dealt in connection with this Amendment other than RE:Align, Inc.

5.Confirmation. Except, as and to the extent modified by this Amendment, all provisions of the Lease shall remain in full force and effect. In the event of a conflict between the terms of the Lease and the terms of this Amendment, the terms in this Amendment shall control.

6.Counterparts. This Amendment may be executed in any number of counterparts, including counterparts transmitted by facsimile or electronic mail, each of which shall be deemed an original for all purposes, and all counterparts shall constitute one and the same instrument.

 

 

 

 

7.Electronic Signatures. Landlord and Tenant consent to the use of electronic signatures on this Amendment and all documents relating to the Lease and this Amendment, and any amendments to any of the foregoing (collectively, the "Lease Documents"). Landlord and Tenant agree that any electronic signatures appearing on the Lease Documents are the same as handwritten signatures for the purposes of validity, enforceability and admissibility, and that any electronically signed Lease Document shall, for all purposes of the Lease Documents and applicable law, be deemed to be "written" or "in writing", to have been executed, and to constitute an original written record when printed, and shall be fully admissible in any legal proceeding. For purposes hereof, "electronic signature" shall have the meaning set forth in the Uniform Electronic Transactions Act, as the same may be amended from time to time.

IN WITNESS WHEREOF, Landlord and Tenant agree to the foregoing as evidenced by
 affixing their signatures below.

 

 

		
	
LANDLORD:
	
TENANT:

	
 
	
 

	
SB CORPORATE CENTRE III-IV, LLC,
a Delaware limited liability company
	
EVOKE PHARMA, INC.

a Delaware corporation

	
 
	
 

	
By:  American Assets Trust Management, LLC
        a Delaware limited liability company, as Agent
	
By:  s/Matt D’Onofrio

	
 
	
 

	
        By:  s/Adam Wyll

                Executive V.P. and COO
	
Name:  Matt D’Onofrio

	
 
	
 

	
        By:  s/Steven M. Center
                V.P. of Office Properties
	
Title:    CBO

	
 
	
 

	
Dated:  December 6, 2019
	
Dated:  December 6, 2019

 

2Exhibit 4.7

 

DESCRIPTION OF CAPITAL STOCK 

 

The following summarizes the material terms of the capital
stock of Protalix BioTherapeutics, Inc. We are a Delaware corporation. The rights of our stockholders are governed by the
Delaware General Corporation Law (the “DGCL”) and by our Certificate of Incorporation, as amended, and our
Bylaws, which are exhibits to our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the
 “Commission”) and available at www.sec.gov. The following summary is qualified in its entirety by
reference to the applicable provisions of the DGCL and our Certificate of Incorporation, as amended, and Bylaws, which are
subject to future amendment in accordance with the provisions thereof. Our common stock is the only class of our securities
registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

Authorized Capital Stock 

 

General. Our charter provides that we may issue up to
120,000,000 shares of common stock, par value $0.001 per share, and 100,000,000 shares of preferred stock, par value $0.0001 per
share. The number of shares of our common stock issued and outstanding as of a recent date is set forth on the cover page of our
most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q filed with the Commission. We currently have
no outstanding shares of preferred stock.

 

Common Stock 

 

Voting Rights. Holders of our common stock are entitled
to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Accordingly,
holders of a majority of the shares of common stock entitled to vote in any election of directors may elect all of the directors
standing for election.

 

Dividends. Subject to the preferential rights, if
any, of the holders of any outstanding series of our preferred stock, holders of shares of our common stock are entitled to receive
dividends when, as and if declared by our Board of Directors (our “Board”) out of funds legally available therefor.

 

Dividend Policy. We have never declared or paid
any cash dividends on our capital stock. We currently intend to retain any future earnings to finance the growth and development
of our business and therefore do not anticipate paying any cash dividends in the foreseeable future. Any future determination to
pay cash dividends will be at the discretion of our Board and will depend upon our financial condition, operating results, capital
requirements, covenants in our debt instruments (if any), and such other factors as our Board deems relevant.

 

Liquidation. In the event of our liquidation, dissolution
or winding-up, after payment of all of our debts and liabilities, the holders of our common stock are entitled to share ratably
in all remaining assets available for distribution after the payment of debts and liabilities and after provision has been made
for each class of stock, if any, having preferences over our common stock. Holders of our common stock, as such, have no preemptive
or other rights and there are no redemption provisions applicable to our common stock. All of our outstanding shares of common
stock are fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to, and may
be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate and issue
in the future. In accordance with the rules of the Tel Aviv Stock Exchange, we are allowed to issue securities with preferential
rights relating to dividends, but such securities may not have voting rights.

 

Other Rights. The holders of our common stock have
no preemptive rights and no rights to convert their common stock into any other securities, and our common stock is not subject
to any redemption or sinking fund provisions.

 

Preferred Stock 

 

Our Certificate of Incorporation, as amended, authorizes the
issuance of up to 100,000,000 shares of preferred stock with such voting rights, rights of redemption and other relative rights
and preferences as may be determined from time to time by our Board. Accordingly, our Board is empowered, without stockholder approval,
to issue preferred stock with dividend, liquidation, conversion, voting or other rights which could adversely affect the voting
power or other rights of the holders of our common stock. The preferred stock could be utilized, under certain circumstances, as
a method of discouraging, delaying or preventing a change in control of our company.

 

     

     

    

 

Anti-Takeover Effects of Provisions of Delaware Law, Our
Certificate of Incorporation, as Amended, and Our By-laws 

 

Delaware statutory law, our Certificate of Incorporation, as
amended, and our Bylaws contain provisions that could make acquisition of our Company by means of a tender offer, a proxy contest
or otherwise more difficult. These provisions are intended to discourage certain types of coercive takeover practices and takeover
bids that our Board may consider inadequate and to encourage persons seeking to acquire control of us to first negotiate with our
Board. We believe that the benefits of increased protection of our ability to negotiate with the proponent of an unfriendly or
unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging takeover or acquisition proposals
because, among other things, negotiation of these proposals could result in an improvement of their terms. The description of our
Certificate of Incorporation, as amended, and our Bylaws set forth below is only a summary and is qualified in its entirety by
reference to our amended and restated certificate of incorporation and amended and restated Bylaws, which are exhibits to our most
recent Annual Report on Form 10-K.

 

Blank Check Preferred Stock.  Our amended and
restated certificate of incorporation permits us to issue, without any further vote or action by the stockholders, up to 100,000,000
shares of preferred stock in one or more series and, with respect to each such series, to fix the number of shares constituting
the series and the designation of the series, the voting powers (if any) of the shares of the series, and the preferences and relative,
participating, optional and other rights, if any, and any qualifications, limitations or restrictions, of the shares of such series.
The ability to issue such preferred stock could discourage potential acquisition proposals and could delay or prevent a change
in control.

 

Number of Directors; Filling Vacancies; Removal.  Our
Bylaws provide that the number of directors which shall constitute the whole of the Board shall be fixed from time to time by resolution
of the Board. Directors shall be elected by a plurality vote of the shares represented in person or by proxy at the annual meeting
of stockholders in each year and entitled to vote on the election of directors. Elected directors shall hold office until the next
annual meeting and until their successors shall be duly elected and qualified. Directors need not be stockholders. If, for any
cause, the Board shall not have been elected at an annual meeting, they may be elected as soon thereafter as convenient at a special
meeting of stockholders called for that purpose in the manner provided in our Bylaws. In addition, our amended and restated certificate
of incorporation and amended and restated Bylaws provide that a Board vacancy resulting from the death, removal or resignation
of a director, as well as a vacancy resulting from an increase in the number of directors or if the stockholders fail at any meeting
of stockholders at which directors are to be elected to elect the number of directors then constituting the whole Board, may be
filled solely by the affirmative vote of a majority of the remaining directors then in office even though that may be less than
a quorum of the Board.

 

Special Meetings. Special Meetings of our stockholders
may be called, for any purpose or purposes, by the Chairman of the Board or the President or the Board of Directors at any time.
Upon written request of any stockholder or stockholders holding in the aggregate not less than 10% of all of the votes entitled
to be cast on any issue proposed to be considered at the Special Meeting signed, dated and delivered in person or sent by registered
mail to the Chairman of the Board, President or Secretary of our company, the Secretary shall call a special meeting of stockholders
to be held at the principal office of the corporation or at such place and at such time as the Secretary may fix, such meeting
to be held not less than 10 nor more than 60 days after the receipt of such request, and if the Secretary shall neglect or refuse
to call such meeting within seven days after the receipt of such request, the stockholder making such request may do so.

 

No Stockholder Action by Written Consent Unless Approved
by the Board. Our Bylaws requires that all actions to be taken by stockholders must be taken at a duly called annual or
special meeting, and stockholders are not permitted to act by written consent. These provisions will make it more difficult for
stockholders to take an action opposed by our Board.

 

     

     

    

 

Section 203 of the Delaware General Corporation Law. Section 203
of the DGCL provides that, subject to certain specified exceptions, a corporation will not engage in any “business combination”
with any “interested stockholder” for a three-year period following the time that such stockholder becomes an interested
stockholder unless (1) before that time, the board of directors of the corporation approved either the business combination
or the transaction which resulted in the stockholder becoming an interested stockholder, (2) upon consummation of the transaction
which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting
stock of the corporation outstanding at the time the transaction commenced (excluding certain shares) or (3) on or after such
time, both the board of directors of the corporation and at least 662/3% of the outstanding voting stock
which is not owned by the interested stockholder approves the business combination. Section 203 of the DGCL generally defines
an “interested stockholder” to include (x) any person that owns 15% or more of the outstanding voting stock of
the corporation, or is an affiliate or associate of the corporation and owned 15% or more of the outstanding voting stock of the
corporation at any time within three years immediately prior to the relevant date and (y) the affiliates and associates of
any such person.

 

Section 203 of the DGCL generally defines a “business
combination” to include (1) any merger or consolidation with an interested stockholder or other entity if the merger
or consolidation is caused by the interested stockholder and as a result section (a) of Section 203 is no longer applicable to
the surviving entity, (2) sales or other dispositions of 10% or more of the corporation’s assets with or to an interested
stockholder, (3) certain transactions resulting in the issuance or transfer to the interested stockholder of any stock of
the corporation or its subsidiaries, (4) certain transactions which would increase the proportionate share of the stock of
the corporation or its subsidiaries owned by the interested stockholder and (5) receipt by the interested stockholder of the
benefit (except proportionately as a stockholder) of any loans, advances, guarantees, pledges, or other financial benefits.

 

We have elected not to be subject to
Section 203 of the DGCL.

 

Transfer Agent and Registrar 

 

The transfer agent and registrar for our common stock is American
Stock Transfer & Trust Company.

 

Listing Information

 

Our common stock is listed on the NYSE American and the Tel
Aviv Stock Exchange under the symbol “PLX.”

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]